Clinical Trials Logo

GIST clinical trials

View clinical trials related to GIST.

Filter by:
  • Terminated  
  • Page 1

NCT ID: NCT01089595 Terminated - GIST Clinical Trials

Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST)

Start date: February 2009
Phase: Phase 2
Study type: Interventional

Patients with advanced GIST are treated with imatinib. This study seeks to look at a new therapeutic agent at the time of tumor progression following treatment with 600-800 mg daily of imatinib. The study is looking to see if Nilotinib (tasigna) alone or in combination with imatinib (gleevec) is more effective at controlling disease.